Jean-Jacques Goy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Jacques Goy has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
Mario Togni
Cardiology University & Hospital Fribourg Fribourg Switzerland
12 shared publicationsStéphane Cook
Cardiology Division, University & University Hospital Fribourg, Fribourg, Switzerland
11 shared publications- Stéphane Cook
Department of Cardiology, HFR—Fribourg Cantonal Hospital and University, 1708 Fribourg, Switzerland
10 shared publications - Jean-Christophe Stauffer
Service de Cardiologie, Hôpital Cantonal, Fribourg, Switzerland
7 shared publications Diego Arroyo
Cardiology University & Hospital Fribourg Fribourg Switzerland
6 shared publications- Serban Puricel
Department of Cardiology, University and Hospital Fribourg, Fribourg, Switzerland
6 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 15 (08) , 5997-6003
Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study
Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study
- 1 August 2024
- Published by MediaSphere Medical LLC in Journal of Innovations in Cardiac Rhythm Management
- Vol. 15 (08) , 5997-6003
Open AccessComparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study
Comparison of Postoperative Continuous Wireless Cardiac Rhythm Monitoring with Traditional Telemetry in Cardiac Surgery Patients: the SMART-TEL Study
- Open Access
- 10 May 2024
- Published by MDPI AG in Preprints.org
Automatic Double Check Monitoring of Continuous Fluid Excretion and Urine Output
Background: Nowadays vital signs in clinics are electronically monitored excepted for urine output which still requires, manual recording, which is subject to human errors. We, in-vitro, assessed in this study the ability a novel electronic device to measure by a combination of two different methods, the real time flow-output, like urine output. Methods: Flow or urine output was measured by a combination technique of gravimetry using a dynamometer and capacitive sensing to improve precision. Data were obtained in 3 different situations, low, medium, and high flow. Results: Three different situations were tested: full or empty dead space and Pasteur’s chamber. The differences between the injected and measured volume varies from 0 to 5 ml representing a maximal error of 3 % regardless of the volume injected and the flow in ml/hour. The capacitive sensors behave as expected with a parallel curve of the expected and measured flow. Conclusion: We have shown in this in-vitro study that the combination of gravimetry and capacitive sensors analysis allow accurate measurement of volume and flow-output. Clinical trials should be conducted to confirm its usefulness in urine output measurement in the real life.
- 10 May 2024
- Published by MDPI AG in Preprints.org
Open AccessAutomatic Double Check Monitoring of Continuous Fluid Excretion and Urine Output
Background: Nowadays vital signs in clinics are electronically monitored excepted for urine output which still requires, manual recording, which is subject to human errors. We, in-vitro, assessed in this study the ability a novel electronic device to measure by a combination of two different methods, the real time flow-output, like urine output. Methods: Flow or urine output was measured by a combination technique of gravimetry using a dynamometer and capacitive sensing to improve precision. Data were obtained in 3 different situations, low, medium, and high flow. Results: Three different situations were tested: full or empty dead space and Pasteur’s chamber. The differences between the injected and measured volume varies from 0 to 5 ml representing a maximal error of 3 % regardless of the volume injected and the flow in ml/hour. The capacitive sensors behave as expected with a parallel curve of the expected and measured flow. Conclusion: We have shown in this in-vitro study that the combination of gravimetry and capacitive sensors analysis allow accurate measurement of volume and flow-output. Clinical trials should be conducted to confirm its usefulness in urine output measurement in the real life.
- Open Access
- 24 March 2022
- Published by Springer Nature in BMC Anesthesiology
- Vol. 22 (1) , 1-7
Performance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers
Background: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter. Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2. We compared the accuracy of SpO2 reading from the SmartCardia system with SpO2 using two well established devices (Masimo and Nellcor) as reference. Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots. Results: The mean (SD) differences between SaO2 compared to SpO2 and the devices were as follows: SaO2 versus Masimo 2,12 ± 1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78 ± 0,58% (95% CI − 0,29 to 1,65) and SaO2 versus SmartCardia 0,42 ± 0,24% (95% CI − 0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI − 2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA − 6 to 11 for Masimo, and 0,76 (95% CI 0,5 to − 1) and LoA − 3,5 to 5,0 for Nellcor. ARMS for the 70–100% SaO2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor. Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor. Trial registration: The present trial was prospectively registered at UCSF record (registration number:10–00437), on March 8, 2021.
- 24 March 2022
- Published by Springer Nature in BMC Anesthesiology
- Vol. 22 (1) , 1-7
Open AccessPerformance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers
Background: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter. Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2. We compared the accuracy of SpO2 reading from the SmartCardia system with SpO2 using two well established devices (Masimo and Nellcor) as reference. Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots. Results: The mean (SD) differences between SaO2 compared to SpO2 and the devices were as follows: SaO2 versus Masimo 2,12 ± 1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78 ± 0,58% (95% CI − 0,29 to 1,65) and SaO2 versus SmartCardia 0,42 ± 0,24% (95% CI − 0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI − 2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA − 6 to 11 for Masimo, and 0,76 (95% CI 0,5 to − 1) and LoA − 3,5 to 5,0 for Nellcor. ARMS for the 70–100% SaO2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor. Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor. Trial registration: The present trial was prospectively registered at UCSF record (registration number:10–00437), on March 8, 2021.
- Open Access
- 21 February 2022
- Published by Springer Nature in Research Square
Performance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers.
Backgroud: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter.Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2 . We compared the accuracy of SpO 2 reading from the SmartCardia system with SaO2 using two well established devices (Masimo and Nellcor ) as reference.Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots.Results: The mean (SD) differences between SpO2 compared to SaO2 and the devices were as follows: SaO2 versus Masimo 2,12±1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78±0,58 % (95 % CI -0,29 to 1,65) and SaO2 versus SmartCardia 0,42±0,24 % (95% CI -0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI -2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA -6 to 11 for Masimo, and 0,76 (95% CI 0,5 to -1) and LoA -3,5 to 5,0 for Nellcor. ARMS for the 70-100% SaO 2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor.Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor.Trial registration: The present trial was prospectively registered at UCSF record (registration number:10-00437), on March 8, 2021.
- 21 February 2022
- Published by Springer Nature in Research Square
Open AccessPerformance of the new SmartCardia wireless, wearable oximeter: a comparison with arterial SaO2 in healthy volunteers.
Backgroud: Our goal was to evaluate the performance of a new wearable arm located pulse oximeter.Methods: Twelve volunteers were monitored with three pulse oximeters and underwent desaturation to 70% SaO2 . We compared the accuracy of SpO 2 reading from the SmartCardia system with SaO2 using two well established devices (Masimo and Nellcor ) as reference.Oximetry was performed at different level of oxygen saturation varying from 70 to 100%. Bias, ARMS and precision were evaluated using Bland-Altman plots.Results: The mean (SD) differences between SpO2 compared to SaO2 and the devices were as follows: SaO2 versus Masimo 2,12±1,01% (95% CI 1,45 to 2,79), SaO2 versus Nellcor 0,78±0,58 % (95 % CI -0,29 to 1,65) and SaO2 versus SmartCardia 0,42±0,24 % (95% CI -0,64 to 1,46). The bias between SmartCardia, Masimo, Nellcor devices and SaO2 was 0.16 (95% CI 0.05 to 0.33) and LoA (level of agreements) 2.96 (95% CI -2,68 to 2,89) for SmartCardia, 2,02 (95% CI 1,49 to 2,54) and LoA -6 to 11 for Masimo, and 0,76 (95% CI 0,5 to -1) and LoA -3,5 to 5,0 for Nellcor. ARMS for the 70-100% SaO 2 range was 1,4 for SmartCardia, 5,0 for Masimo and 2,31 for Nellcor.Conclusions: The new wireless SmartCardia SpO2 measurement system demonstrated in-line results, bias, ARMS and precision in healthy volunteers, when compared with the gold standard SaO2 and with two well established systems, Masimo and Nellcor.Trial registration: The present trial was prospectively registered at UCSF record (registration number:10-00437), on March 8, 2021.
- Open Access
- 1 September 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (11) , 1367-1369
Chest Pain and Hemodynamic Instability in a Young Woman
- 1 September 2021
- Published by Elsevier in JACC: Case Reports
- Vol. 3 (11) , 1367-1369
Open AccessChest Pain and Hemodynamic Instability in a Young Woman
- Open Access
- 26 August 2021
- Published by Elsevier in JTCVS Open
- Vol. 8, 193-202
Short-term outcomes of aortic valve neocuspidization for various aortic valve diseases
- 26 August 2021
- Published by Elsevier in JTCVS Open
- Vol. 8, 193-202
Open AccessShort-term outcomes of aortic valve neocuspidization for various aortic valve diseases
- Open Access
- 26 June 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (3) , 523-532
Five‐year angiographic,OCTand clinical outcomes of a randomized comparison of everolimus and biolimus‐eluting coronary stents with everolimus‐eluting bioresorbable vascular scaffolds
Aims: To compare 5‐year angiographic, optical coherence tomography (OCT), and clinical outcomes between patients treated with bioresorbable vascular scaffolds (BVS) and drug‐eluting stents (DES).Methods: The EverBio‐2 trial (Comparison of Everolimus‐ and Biolimus‐Eluting Coronary Stents with Everolimus‐Eluting Bioresorbable Vascular Scaffold) was a single‐center, assessor‐blinded, randomized controlled trial in which 240 patients were randomly allocated (1:1:1) to BVS, everolimus‐eluting (EES) or biolimus‐eluting (BES) DES. Clinical follow‐up was scheduled up to 5 years. All patients, alive and who did not have repeat revascularization of the target lesion during follow‐up were asked to return for angiographic follow‐up at 5 years.Results: Five‐year angiographic follow‐up was completed in 122 patients (51%) and OCT analysis was performed in 86 (36%) patients. In‐stent late lumen loss was similar in both groups with 0.50 ± 0.38 mm in BVS versus 0.58 ± 0.36 mm in EES/BES,p = 0.20. Clinical follow‐up was complete in 232 patients (97%) at 5 years. The rate of the device‐oriented endpoint was 22% in the BVS and 18% in the EES/BES group (p = 0.49). The patient‐oriented composite endpoint occurred in 40% of BVS‐ and 43% of EES/BES‐treated patients (p = 0.72) at 5 years. No acute coronary syndrome due to stent thrombosis was detected after 2 years. Complete BVS strut resorption was observed at 5 years in the OCT subgroup.Conclusion: Five‐year clinical outcomes were similar between BVS and DES patients as well as angiographic outcomes in a selected subgroup. However, a definitive conclusion cannot be drawn because the EverBio‐2 trial was not powered for clinical and angiographic endpoints at 5 years of follow‐up.
- 26 June 2021
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 99 (3) , 523-532
Open AccessFive‐year angiographic,OCTand clinical outcomes of a randomized comparison of everolimus and biolimus‐eluting coronary stents with everolimus‐eluting bioresorbable vascular scaffolds
Aims: To compare 5‐year angiographic, optical coherence tomography (OCT), and clinical outcomes between patients treated with bioresorbable vascular scaffolds (BVS) and drug‐eluting stents (DES).Methods: The EverBio‐2 trial (Comparison of Everolimus‐ and Biolimus‐Eluting Coronary Stents with Everolimus‐Eluting Bioresorbable Vascular Scaffold) was a single‐center, assessor‐blinded, randomized controlled trial in which 240 patients were randomly allocated (1:1:1) to BVS, everolimus‐eluting (EES) or biolimus‐eluting (BES) DES. Clinical follow‐up was scheduled up to 5 years. All patients, alive and who did not have repeat revascularization of the target lesion during follow‐up were asked to return for angiographic follow‐up at 5 years.Results: Five‐year angiographic follow‐up was completed in 122 patients (51%) and OCT analysis was performed in 86 (36%) patients. In‐stent late lumen loss was similar in both groups with 0.50 ± 0.38 mm in BVS versus 0.58 ± 0.36 mm in EES/BES,p = 0.20. Clinical follow‐up was complete in 232 patients (97%) at 5 years. The rate of the device‐oriented endpoint was 22% in the BVS and 18% in the EES/BES group (p = 0.49). The patient‐oriented composite endpoint occurred in 40% of BVS‐ and 43% of EES/BES‐treated patients (p = 0.72) at 5 years. No acute coronary syndrome due to stent thrombosis was detected after 2 years. Complete BVS strut resorption was observed at 5 years in the OCT subgroup.Conclusion: Five‐year clinical outcomes were similar between BVS and DES patients as well as angiographic outcomes in a selected subgroup. However, a definitive conclusion cannot be drawn because the EverBio‐2 trial was not powered for clinical and angiographic endpoints at 5 years of follow‐up.
- 1 May 2021
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 42 (5) , 365-366
Des paresthésies d’un doigt
- 1 May 2021
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 42 (5) , 365-366
Des paresthésies d’un doigt
- 1 April 2021
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (8) , 923-924
Radial Aneurysmal AV Fistula as a Complication of Coronary Angioplasty
- 1 April 2021
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 14 (8) , 923-924
Radial Aneurysmal AV Fistula as a Complication of Coronary Angioplasty
- Open Access
- 30 November 2020
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 7
Cardiac Ambulatory Monitoring: New Wireless Device Validated Against Conventional Holter Monitoring in a Case Series
Background: Cardiac arrhythmias are very common but underdiagnosed due to their transient and asymptomatic nature. An optimization of arrhythmia detection would permit to better treat patients and could substantially reduce morbidity and mortality. The SmartCardia ScaAI wireless patch is a novel CE IIa approved, single-lead electrocardiographic (ECG) ambulatory monitor designed for cardiac arrhythmias detection.Hypothesis: The accuracy of the new SmartCardia wireless patch to detect arrhythmias is comparable to the conventional Holter monitoring.Methods: Patients referred for a suspicion of arrhythmia between February and March 2020 were included in the trial. Simultaneous ambulatory ECG were recorded using a conventional 24-h Holter and the SmartCardia. The primary endpoint was the detection of cardiac arrhythmias over the total wear time of the devices, defined as premature atrial contraction (PAC), supraventricular tachycardia ≥3 beats, premature ventricular contraction (PVC), and ventricular tachycardia ≥3 beats. Conduction abnormalities, pause ≥2 s and atrioventricular block (AVB), were also tracked. McNemar's test was used to compare the matched pairs of data from both devices.Results: A total of 40 patients were included in the trial. Over the total wear time, there was no significant difference between the devices for ventricular and supraventricular arrhythmias detection. Pauses and AVB were equally identified by the two devices in three patients.Conclusion: Over the total wear time, the SmartCardia device showed an accuracy to detect arrhythmia similar to the 24-h Holter monitoring: single-lead, adhesive-patch monitoring might become an interesting alternative to the conventional Holter monitoring.
- 30 November 2020
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 7
Open AccessCardiac Ambulatory Monitoring: New Wireless Device Validated Against Conventional Holter Monitoring in a Case Series
Background: Cardiac arrhythmias are very common but underdiagnosed due to their transient and asymptomatic nature. An optimization of arrhythmia detection would permit to better treat patients and could substantially reduce morbidity and mortality. The SmartCardia ScaAI wireless patch is a novel CE IIa approved, single-lead electrocardiographic (ECG) ambulatory monitor designed for cardiac arrhythmias detection.Hypothesis: The accuracy of the new SmartCardia wireless patch to detect arrhythmias is comparable to the conventional Holter monitoring.Methods: Patients referred for a suspicion of arrhythmia between February and March 2020 were included in the trial. Simultaneous ambulatory ECG were recorded using a conventional 24-h Holter and the SmartCardia. The primary endpoint was the detection of cardiac arrhythmias over the total wear time of the devices, defined as premature atrial contraction (PAC), supraventricular tachycardia ≥3 beats, premature ventricular contraction (PVC), and ventricular tachycardia ≥3 beats. Conduction abnormalities, pause ≥2 s and atrioventricular block (AVB), were also tracked. McNemar's test was used to compare the matched pairs of data from both devices.Results: A total of 40 patients were included in the trial. Over the total wear time, there was no significant difference between the devices for ventricular and supraventricular arrhythmias detection. Pauses and AVB were equally identified by the two devices in three patients.Conclusion: Over the total wear time, the SmartCardia device showed an accuracy to detect arrhythmia similar to the 24-h Holter monitoring: single-lead, adhesive-patch monitoring might become an interesting alternative to the conventional Holter monitoring.